background
banner

JYLAMVO 2mg/ml Price

Active Substance: Methotrexate.

683
UAD , based on 7541 reviews.
View Drug details

Overview

Welcome to Dwaey, specifically on JYLAMVO 2mg/ml Oral solution page.
This medicine contains an important and useful components, as it consists of Methotrexate.
JYLAMVO 2mg/ml is available in the market in concentration 2mg/ml and in the form of Oral solution.

Therakind (Europe) Limited is the producer of JYLAMVO 2mg/ml and it is imported from IRELAND, The most popular alternatives of JYLAMVO 2mg/ml are listed downward .

Mode Of Action

Methotrexate is a folic acid antagonist that inhibits DNA synthesis. It irreversibly binds to dihydrofolate reductase, inhibiting the formation of reduced folates, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid synthesis.

Indication

  • Burkitt's lymphoma
  • Choriocarcinoma
  • Mycosis fungoides
  • Crohn's disease
  • Psoriasis
  • Osteosarcoma
  • Breast cancer
  • lymphosarcoma
  • Acute lymphoblastic leukaemia
  • Rheumatoid arthritis

Precaution

Hepatic or renal impairment, bone marrow depression, elderly, neonates. Ulcerative disorders of the GI tract. Monitor haematological, renal and hepatic function, and GI toxicity regularly. Lactation: Drug excreted in breast milk; do not nurse

Side Effects

  • >10% Arachnoiditis with intrathecal administration
  • Subacute toxicity with intrathecal administration (paralysis of extremities
  • cranial nerve palsy
  • seizure or coma)
  • Demyelinating encephalopathy with cranial irradiation or other systemic chemotherapy
  • Reddening of skin
  • Hyperuricemia
  • Ulcerative stomatitis
  • Glossitis
  • Gingivitis
  • Nausea and vomiting
  • Diarrhea
  • Anorexia
  • Intestinal perforation
  • Mucositis (dose-dependent)
  • Leukopenia
  • Thrombocytopenia
  • Renal failure
  • Azotemia
  • Nephropathy
  • Pharyngitis 1-10% Alopecia
  • Photosensitivity
  • Rash
  • Abdominal distress
  • Malaise
  • Fatigue
  • Chills
  • fever
  • Decreased resistance to infection
  • Gastrointestinal hemorrhage
  • Myelosuppression
  • Disorders of lung
  • interstitial pneumonia (acute
  • chronic)
  • Atrophy of liver
  • cirrhosis
  • hepatic fibrosis or necrosis
  • elevated liver function tests
  • hepatic failure Potentially Fatal: Pulmonary reactions (e.g. interstitial lung disease); neurotoxicity (e.g. leukoencephalopathy
  • paresis
  • demyelination) with intrathecal use; foetal deaths.

Contra indication

Severe renal or hepatic impairment, pre-existing profound bone marrow suppression in patients with psoriasis or rheumatoid arthritis, alcoholic liver disease, AIDS, pre-existing blood dyscrasias, pregnancy (in patients with psoriasis or rheumatoid arthritis), breast-feeding.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Interaction

Decreased effectiveness with folic acid and its derivatives. Potentially Fatal: Increased toxicity with NSAIDs and salicylates; probenecid; some penicillins; aminoglycosides neomycin and paromomycin; sulfonamides such as sulfafurazole and sulfamethoxazole; co-trimoxazole or trimethoprim; nephrotoxic agents (e.g. cisplatin); ciclosporin; etretinate. Synergistic enhancement of effects with fluorouracil. Increased bioavailability of mercaptopurine. Reduces serum-valproate concentrations. Reduced serum concentrations with colestyramine. Increased serum concentrations with omeprazole.

Alternatives Price List

  • METHOTREXATE 50mg/2mlUAD 74
  • METHOTREXATE 500mg/20mlUAD 247
  • METHOTREXATE 500mg/20mlUAD 131
  • METHOTREXATE 20mg/2mlUAD 30
  • METHOTREXATE 1g/10mlUAD 236

Releated Products

banner

Report Price Error

Please feel welcome to contact Us with any price or medical error. Our doctors will receive any reports.